We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Acute Erythroderma in a Patient Receiving TNF-α-Blocking Therapy for Hidradenitis Suppurativa.
- Authors
Benhadou, Farida; Hellgren, Guillaume; Willaert, Fabienne; del Marmol, Véronique
- Abstract
Tumor necrosis factor-α (TNF-α) normally binds to TNF-α receptors, leading to the inflammatory response of autoimmune diseases. Adalimumab is a TNF-inhibiting, anti-inflammatory, biological medication which binds to TNF-α, thus reducing this inflammatory response. The use of TNF-α-inhibiting medication, such as adalimumab, being the first FDA-approved treatment for hidradenitis suppurativa, has drastically changed the management of dermatological diseases. One rarely reported manifestation that occurs as a side effect associated with the use of TNF-α-blocking agents is erythroderma. This study, for the first time, reports the case of a patient suffering from hidradenitis suppurativa with concomitant psoriasis, who developed a severe and acute erythrodermic rash after the start of adalimumab therapy.
- Subjects
TUMOR necrosis factors; HIDRADENITIS suppurativa; PSORIASIS
- Publication
Case Reports in Dermatology, 2018, Vol 10, Issue 1, p7
- ISSN
1662-6567
- Publication type
Case Study
- DOI
10.1159/000485911